NCT06998056Phase 2Completed

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-12-04Actual
Enrollment · participants101Actual
Source updated2026-11-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 100 participants (planned). After: 101 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jun 2026. After: 4 Dec 2025.

Recruitment status changed

Before: Recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview